ILLUSTRATION   Open Access    

Gantt chart for updated OS and PFS after cancer targeted therapy

More Information
  • 加载中
  • [1] Smith, M. R., Saad, F., Chowdhury, S., et al. (2021). Apalutamide and overall survival in prostate cancer. Eur. Urol. 79, 150−158.

    View in Article CrossRef Google Scholar

    [2] Skoulidis, F., Li, B. T., Dy, G. K., et al. (2021). Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 384, 2371–2381.

    View in Article Google Scholar

    [3] Diaz, L. A. Jr, Shiu, K. K., Kim, T. W., et al. (2022). Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet. Oncol. 23, 659−670.

    View in Article CrossRef Google Scholar

  • Cite this article:

    Du X., Lu X., and Cao X. (2023). Gantt chart for updated OS and PFS after cancer targeted therapy. The Innovation Medicine 1(1), 100008. https://doi.org/10.59717/j.xinn-med.2023.100008
    Du X., Lu X., and Cao X. (2023). Gantt chart for updated OS and PFS after cancer targeted therapy. The Innovation Medicine 1(1), 100008. https://doi.org/10.59717/j.xinn-med.2023.100008

Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(2367) PDF downloads(456) Cited by(0)

Relative Articles

Article Contents

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint